ABCB11 and intrahepatic cholestasis: While the molecular events in the livers of these patients are unknown, this clinical setting is consistent with our model (Fig 8) in which statin-induced miR-33 represses both ABCB11 and ATP8B1, thus decreasing bile secretion and eventually leading to intrahepatic cholestasis.